---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000003"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:51:22.989181+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M

## Summary
- Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.
- Full-year net revenues $437.8M vs $349.8M in 2020; GAAP net income $62.1M vs $1.4M.
- Adjusted non-GAAP diluted EPS $0.42 for Q4 and $1.37 for full year.
- CEO cites continued growth of higher-margin products and expects pipeline milestones in 2022.

## SEC filing metadata
- accession: 0001297184-22-000003
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/0001297184-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/amph-20220310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000003
- JSON: https://secwatch.observer/filing/0001297184-22-000003.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.